Dosing |
|
Dosing: Adult Vulvovaginal candidiasis: Vaginal: Insert 1 applicatorful in vagina, just prior to bedtime, as a single dose
Dosing: Geriatric Refer to adult dosing. |
|
Use |
|
Local treatment of vulvovaginal candidiasis |
|
|
Contraindications |
|
Hypersensitivity to tioconazole or any component of the formulation |
|
Warnings / Precautions Drug |
|
Concerns related to adverse effects:• Irritation: If irritation or sensitization occurs, discontinue use. Dosage form specific issues:• Petrolatum-based: Petrolatum-based vaginal products may damage rubber or latex condoms or diaphragms; separate use by 3 days. Metabolism/Transport Effects Inhibits CYP1A2 (weak), 2A6 (weak), 2C9 (weak), 2C19 (weak), 2D6 (weak), 2E1 (weak) |
|
Interactions |
|
There are no known significant interactions. |
|
Pregnancy |
|
|
|
Lactation |
|
Excretion in breast milk unknown/not recommended |
|
|
Mechanism of Action |
|
A 1-substituted imidazole derivative with a broad antifungal spectrum against a wide variety of dermatophytes and yeasts, including Trichophyton mentagrophytes, T. rubrum, T. erinacei, T. tonsurans, Microsporum canis, Microsporum gypseum, and Candida albicans. Both agents appear to be similarly effective against Epidermophyton floccosum. |
|
Pharmacodynamics / Kinetics |
|
Onset of action: Some improvement: Within 24 hours; Complete relief: Within 7 days Absorption: Intravaginal: Systemic (small amounts) Distribution: Vaginal fluid: 24-72 hours Excretion: Urine and feces |
|
